key: cord-0682558-ugi5pntt
authors: Gibbs, Derek V.; Shreenivas, Satya S.; Hudock, Kristin M.
title: Role of Acute Thrombosis in COVID-19
date: 2022-03-25
journal: Crit Care Clin
DOI: 10.1016/j.ccc.2022.03.003
sha: 8f7c9a1f2973c4055bfee80ef9ef419624362801
doc_id: 682558
cord_uid: ugi5pntt

Patients with SARS-CoV-2 are prone to venous, cerebrovascular and coronary thrombi, particularly those with severe COVID-19. The pathogenesis is multifactorial and likely involves proinflammatory cascades, development of coagulopathy and neutrophil extracellular traps (NETs), although further investigations are needed. Elevated D-dimers are common in patients with COVID-19 and cannot be used in isolation to predict VTE in people with SARS-CoV-2. If given early in hospital admission, therapeutic dose heparin improves clinical outcomes in patients with moderate COVID-19. To date, anti-thrombotics have not improved outcomes in patients with severe COVID-19, possibly because significant tissue damage has already occurred. There is insufficient evidence for routine radiographic evaluation for VTEs in all patients with COVID-19, however, imaging should be considered in the evaluation of patients with sudden clinical deteriorations. Finally, prompt recognition of extra-pulmonary thrombi—particularly in the brain or heart—may be beneficial, but additional evidence is needed and interventional response times may be limited by local resources.

SARS-CoV-2 rapidly spread across the world in late 2019 and early 2020 causing mild to severe multisystem disease. In addition to respiratory symptoms, COVID-19 causes coagulopathy, particularly in critically ill patients. [1] [2] [3] Thrombosis is crucial in infection to protect the host by limiting dissemination of viral and other pathogens, but when uncontrolled can cause tissue damage. 4, 5 The pathogenesis of SARS-CoV-2 is exacerbated by microthrombi and macrothrombi that compromise circulation and threaten organ function. 6 In addition to limiting blood flow, the positive feedback loop of the immune response perpetuating clots further exacerbates inflammation and contributes to disease burden in COVID-19. Herein, we review the latest epidemiology, biologic mechanisms, organ-specific considerations and therapeutic trials regarding thrombosis in COVID-19.

The mechanisms by which SARS-CoV-2 infection promotes coagulopathy include host and virusrelated factors. Neutrophil extracellular traps (NETs) are web-like structures comprised of DNA, histones and immunomodulatory proteins that trap and kill microorganisms. 7, 8 NETs have been implicated in thrombus formation via multiple mechansims. [9] [10] [11] [12] The SARS-CoV-2 virus and plasma from COVID-19 patients can induce neutrophils to form NETs ex vivo. 13, 14 NETs-detected by the presence of MPO-DNA and/or NE-DNA complexes-are increased in the blood of hospitalized patients with COVID-19 compared to healthy controls. 13, 15, 16 NET concentrations correlate with severity of SARS-CoV-2 disease. 14, 16 Histologic analysis of autopsy tissue from patients who died of COVID-19 showed NETs within vascular thrombi, although whether NETs initiate clots or NET formation is activated by platelets at the site of pre-formed clots remains unclear. 15, 17 We have demonstrated that NETs can cause human airway epithelia to increase secretion of IL-1 cytokines, another potential mechanism by which NETs could contribute to COVID-19 pathogenesis. 18 Drugs that affect NETs in COVID are currently being trialed. Endothelial, complement and platelet activation, also contribute to coagulopathy in COVID-19, the details of which are described in recent excellent reviews. 19, 20 Epidemiology of Vascular Thrombi in Patients infected with the SARS CoV-2 virus are at increased risk of thrombosis and coagulopathy for reasons previously described, with coagulopathy itself predicting worse prognosis. In an early study of 184 Dutch ICU patients, 27% of patients were found to have a VTE-most commonly due to PE-while 3.7% had an arterial thrombus. This study was evaluating symptomatic thrombotic events and did not include a universal screen, however, it demonstrated an overall thrombosis rate of 31%, which was higher than seen in other studies. 21 A study which included lower extremity dopplers on admission for 26 COVID-19 patients in two French ICUs found an overall VTE rate of 69%. Moreover, high rates of PE and DVT were observed on subsequent imaging, even in those treated with therapeutic anticoagulation. 22 Another small study employing routine lower extremity dopplers in a French ICU found DVTs in 22 (65%) patients on admission and 27 (79%) after 48 hours. 23 Of note, all three of these studies were limited to 1-2 centers and were performed early in the pandemic when treatment and anticoagulation protocols varied significantly across institutions.

A large cohort study evaluated the incidence of VTE in >3,000 patients in the United States within two weeks of ICU admission. Only three of the 67 sites did routine screening with imaging for most patients at the discretion of the treating team. The VTE incidence was found to be 6.3% in >3,000 patients. 24 This is significantly lower than the initial studies of VTE in COVID-19, however, this US study did not include a universal screening protocol and excluded patients with confirmed or suspected DVT at the time of study enrollment. 24 Given the lack of a universal screening protocol, it is possible that many patients have thrombi that go undetected as they are asymptomatic or the contribution of microthrombi and macrothrombi was underrecognized. Furthermore, it is possible that if these were studies were repeated now, rates of VTE may be further altered by our evolved standard of care treatments, e.g., dexamethasone, for COVID-19. Moreover, we agree with the NIH guidelines that recommends imaging for thrombi as part of the assessment of COVID-19 patients with significant clinical deteriorations, if not contraindicated. 25 

There has been varying reports on the risk of stroke in COVID-19 with rates ranging from 0.5 to 6%. Initial reports from China suggested that the overall rate of strokes and vascular interventions for the general population was decreased during COVID-19. However, this may have been due to external factors including reduced healthcare utilization and decreased use of vascular imaging during initial phases of the pandemic. A cross-sectional study utilizing data from a New York healthcare system discharge and billing database from 24,808 patients (566 of whom were COVID-19 positive) showed an OR of 0.25 of developing stroke compared to age and comorbidity matched COVID-19-negative patients. 26 More recent large meta-analyses suggest an incidence closer to 1.3-1.5%. When looking at the patients with COVID-19 who developed cerebrovascular events, they were approximately 4.5-6 years younger than their non-infected counterparts in the general population. 27, 28 They often had the same cardiovascular risk factors such as coronary artery disease, hypertension and diabetes. One important risk factor for development of stroke is COVID-19 disease severity. 28, 29 In one meta-analysis, patients with severe COVID-19 had an incidence of 3.37% while patients without severe disease had an incidence of 0.6%. 30 It is difficult to know the true incidence of stroke in COVID-19, in part due to critically ill patients-whom are at highest risk of stroke-often being intubated. We suspect that incidence of CVA in critically ill patients is underestimated because: 1) patients are too sick to be transported for brain imaging, 2) neurologic exams are limited in patients on sedation used for mechanical ventilation/proning leading to an underappreciation of potential deficits and 3) patients die before imaging can occur or a meaningful neurologic exam can be completed.

The majority of COVID-19 patients with strokes developed ischemic stroke (around 87%). Additionally, 44.7% of strokes were cryptogenic and 21.9% were cardioembolic. The absence of atherosclerotic disease as a significant etiology to stroke in this population is one possible explanation for the earlier age of onset. Compared to patient's without COVID-19 infection, large vessel occlusion was seen around two and a half times more often. 28 Coronary Thrombosis in COVID-19

Patients with cardiovascular disease are predisposed to COVID-19 infection, and once infected, they are at elevated risk for cardiovascular complications. 31 A significant source of COVID-19-related cardiac risk comes from myocardial injury related to coronary thrombosis. Case series from New York and Wuhan in early 2020 showed patients presenting with ST elevation on electrocardiogram and elevated cardiac biomarkers of injury (Troponin). 32, 33 Troponin elevation as a sign of myocardial injury is an important marker of adverse prognosis in patients with COVID-19; patients with abnormally elevated troponin levels in the setting of COVID-19 are more likely to be admitted to the ICU and are more likely to die. 34 Case series have reported the incidence of acute myocardial injury (defined as both elevated biomarkers and EKG abnormalities) in patients with COVID-19 ranging from 12 to 19.7%. 35, 36 However, other than small case series, the true incidence of myocardial injury with COVID-19 is unclear as these series are mostly in hospitalized patients and we know that patients with comorbidities of coronary artery disease such as hypertension and diabetes are also more likely to be hospitalized with COVID-19. In addition, several case series only examined patients that had undergone coronary angiograms to define the incidence of coronary thrombosis. In many parts of the world, the COVID-19 pandemic changed practice patterns due to healthcare rationing such that patients that might have routinely undergone invasive cardiac testing were instead managed conservatively. For example, in Wuhan, one hospital system's published algorithm for patients with COVID-19 patients presenting with ST elevation myocardial infarction articulated a delay in management of coronary thrombosis in patients with severe pneumonia and in those with less severe pulmonary disease, a fibrinolytic first strategy was recommended. 37 

The burden of coronary thrombosis varies widely, ranging from non-obstructive thrombus to large thrombi burden in multiple vessels. 38 COVID-19 patients with myocardial infarction can have coronary thrombus in epicardial vessels that can be associated with coronary stenosis or plaque rupture, similar to patients without COVID-19. However, there are also numerous reports of COVID-19 patients with epicardial thrombus without any evidence of coronary artery atherosclerotic plaque or stenosis and cases where no epicardial vessel thrombus was seen during coronary angiogram. 39 In these cases, it is likely that microemboli or thrombosis in vessels that are not visible by the naked eye on coronary angiogram could still be causing significant myocardial injury. In a case series of post-mortem examinations of 40 hearts frp, patients that died from COVID-19, 35% had evidence of myocardial necrosis. 40 Of these cases, only 2 (14.2%) had evidence of epicardial coronary artery thrombi, while the rest had evidence of microthrombi in myocardial capillaries, arterioles, and small muscular arteries. 40 Timing of coronary thrombosis during a COVID-19 infection also needs further elucidation but there is some evidence that this is an early phenomenon. In one case series from Lombardy, Italy, 85% of patients diagnosed with coronary thrombosis by coronary angiogram presented with chest pain and ST segment elevations prior to diagnosis of COVID-19 and the remainder were diagnosed with STEMI during the hospitalization. 41 Due to the heterogenous patient population (including many patients that are at high risk for coronary events due to many cardiac comorbidities), it is important to have myocardial ischemia on the differential for new patients presenting with COVID-19 and for COVID-19 patients that clinically decompensate during a hospitalization.

There are several potential mechanisms for why COVID-19 may cause coronary thrombosis. There are many similarities between the potential causes of coronary thrombosis and the postulated causative role of COVID-19 in thrombosis in other vascular distributions. Specifically, there are four proposed hypotheses, which are not mutually exclusive, to explain the large role that cardiovascular system plays in morbidity and mortality in COVID-19: 1) Cardiac tissue is a substrate for SARS-CoV-2 binding.

2) The role of SARS-CoV-2-induced endothelial dysfunction causes acute thrombosis.

3) The proinflammatory immune response to the virus causes acute thrombosis. 4) COVID-19 preferentially affects people with cardiovascular risk factors.

The SARS-CoV-2 virus has an affinity for the ACE receptor, which is highly concentrated in myocardial tissue, and this could explain the role of COVID-19 in causing coronary thrombosis, myocarditis and arrhythmias. The ACE receptor is also found on vascular endothelium and endothelial dysfunction could result in the inciting injury that is further propagated by the pro-inflammatory state of acute infection associated with severe COVID-19 infection. The proinflammatory cascade is known to interfere with the coagulation to form a prothrombotic milieu that can then proceed to acute myocardial infarction as has been shown in other types of acute infection include other types of pneumonia. 42, 43 Finally, all of this is occurring in a patient group with multiple coronary artery disease risk factors including pre-existing coronary artery disease, older age, hypertension, and diabetes. 44 The combination of high affinity for myocardial tissue for SARS-CoV-2 binding, endothelial dysfunction, proinflammatory state, and the at-risk patient cohort all contribute to the risk for coronary thrombosis in patients with COVID-19.

In cases of suspected coronary thrombosis with ST elevation myocardial infarction the recommendation of the American College of Cardiology is to proceed with primary percutaneous coronary intervention (PCI) unless there are limitations in local resources that might result in delayed care. 45 In situations that may result in delay to primary PCI, a fibrinolytic first strategy could be considered. This is similar to recommendations for the care of ST elevation myocardial infarctions in the general population where geography, weather or other systemic delays in care sometimes prevent a primary PCI strategy and fibrinolytics are still used. In cases of non-ST elevation myocardial infarction or in cases where a ST-elevation diagnosis is not clear, efforts should be made to differentiate between demand ischemia from occlusive coronary thrombosis. Tools that could help with such differentiation include trending biomarkers, serial electrocardiograms, and point of care echocardiogram. If the patient is clinically stable and symptom free-depending on the local resources needed for the care of other patients-a deferred strategy can be considered with medical treatment with antiplatelet and antithrombotic agents. Of note, COVID-19 patients frequently present with thrombocytopenia with one study showing 36% of patients diagnosed with COVID-19 presenting with a platelet count of <150,000/ul. 46 The risk/benefit for antiplatelet and antithrombotic therapy in these patients needs to be individualized and careful monitoring for both bleeding and thrombotic complications is essential. Finally, in cases where a patient undergoes a coronary angiogram and no occlusive epicardial disease is found, consideration should then turn towards other causes of elevated troponin elevation including myocarditis, stress-induced cardiomyopathy (Takotsubo), and microvascular coronary ischemia.

There has been a lot of research on whether anticoagulation or antiplatelet therapy changes outcomes and rates of thrombosis in COVID-19 patients. Earlier studies primarily focused on an endpoint of thrombosis and mortality, however, when most of those were negative or showed no benefit to anticoagulation, later studies began to focus on risk stratification with severity of illness, location of treatment (ICU vs floor), and lab evaluation. Additionally, as described herein, the presence of PE or stroke significantly increases mortality. Because of this, there was significant interest in prevention of thrombosis with multicenter clinical trials testing full-dose versus prophylactic-dose anticoagulation as well as different antithrombotic agents.

While the majority of trials focused on anticoagulation on the inpatient side, there are several studies in progress to assess the use of prophylactic dose anticoagulation as an outpatient during SARS-CoV-2 infection. PREVENT-HD trial assessed the safety and efficacy of Xarelto 10mg daily on an outpatient basis for 35 days. 47 Two trials, the OVID trial2 and the ETHIC trial, are comparing 40mg subcutaneous lovenox daily versus placebo. 48 The ACTIV-4b trial looking at apixaban (2.5mg or 5mg) versus aspirin versus placebo. It was stopped early at interim evaluation due to lack of thrombotic events in all arms of the study. 49 Currently, there is insufficient data to support routine use of prophylactic anticoagulation on an outpatient basis.

The ACTION trial was one of the early trials and it compared treatment dose Xarelto (20mg daily) in stable patients and Lovenox at 1mg/kg bid in unstable patients with prophylactic dosing anticoagulation in hospitalized patients followed by Xarelto, all totaling 30 days. 50 Clinically unstable patients had severe COVID-19, a life-threatening comorbidity, required mechanical ventilation or the ICU. It should be noted that in this trial, only 39 of the 615 patients were deemed clinically unstable. There was no difference in the primary outcome of mortality (11.3% in therapeutic arm, 7.6% in prophylactic), but there was a trend towards higher mortality in the treatment arm. There were nonsignificant trends towards lower VTE rate (3.5% in treatment arm, 5.9% in prophylactic arm). The only clinical end-point to reach significance was ISTH defined bleeding, which occurred in 8.3% of patients in the treatment group compared to 2.3% of the patients receiving prophylactic doses of anticoagulation. 50 

A trial of prophylactic Apixiban versus subcutaneous low molecular weight heparin (LMWH) demonstrated a significant decrease in mortality with prophylactic dose apixaban or prophylactic dose enoxaparin when compared to no anticoagulation at all. They also saw a decrease in mortality in the therapeutic dose anticoagulation arms, however, there was no significant difference between therapeutic versus prophylactic. A sub-group analysis revealed that COVID-19 patients with a normal Ddimer < 1.0 did not benefit from anticoagulation while patients with very high D-dimers (>10) did. 51 

The RECOVERY trial was a large multicenter trial in the U.K. looking at treatment of COVID-19 patients admitted in a hospital with moderate dose 150mg aspirin daily to see if the anti-inflammatory effects had any significant decrease in hospitalization stay, progression to ventilator support, or mortality. In total, 14,892 patients were randomized. There was no difference in 28-day mortality or progression to invasive mechanical ventilation between those who did and did not receive aspirin. There was a small but significant increase in discharge from hospital alive at 28 days (OR 1.06) and shorter duration of hospital stay in patients in the aspirin arm. For every 1,000 patients treated with aspirin, there were 6 major bleeding episodes and 6 fewer thromboembolic events. Overall, aspirin did not show evidence of improving mortality or reducing progression of disease. 52 Trials of additional antiplatelet agents are currently ongoing in patients with moderate and severe COVID-19, e.g., NCT04505774.

The majority of data regarding anticoagulation tested heparin, the historical agent of choice in VTE prophylaxis. There are multiple factors that make heparin more attractive than some other agents, such as avoiding drug interactions with tocilizumab that are seen with Xarelto or Apixaban and the potential to reduce inflammation. Three multicenter, international, platform trials assessed the use of heparin: REMAP-CAP, ACTIV-4A, and ATTACC. 53, 54 All of these studies included a group of patients with critical COVID-19-related illness patients (severe) and a group of patients with moderate COVID-19. The definition of critically ill varied slightly between these trials. REMAP-CAP included patients admitted to the ICU and ACTIV-4A enrolled severe patients on >20LNC, regardless of their physical location (taking into accounting that many hospitals were having to expand ICU care beyond the ICU). In an effort to maximize enrollment and rapidly answer urgent clinical questions, these groups combined their data and analyzed the results together. 53, 54 The enrollment of critically ill patients was stopped early in December 2020 when no significant difference was seen in the primary outcome of organ support-free days for those who received therapeutic dose heparin versus usual care dosing (prophylactic or intermediate dose SQ heparin). Sixty-two percent of 534 patients in the therapeutic heparin arm compared to 64.5% of the 564 patients in the usual care arm survived to hospital discharge. There were fewer thrombotic events noted with full-dose anticoagulation (7.2% vs 11.1%) and rates of major bleeding episodes (3.8% vs 2.3%) were similar between groups. It is important to note that the standard of care/prophylactic dose anticoagulation arm used an intermediate dose strategy in 51% of the patients. 54 In contrast to the critically ill group, the moderately ill COVID-19 patients had a significant benefit from therapeutic dose heparin compared to usual care dose heparin. After enrolling 2,219 across the three platforms hospitalized patients, there was a 98.6% probability of increasing organ support-free days with an odds ratio of 1.27. When stratifying by patients with high and low D-dimers the results were unchanged. Major bleeding did occur slightly more frequently in the therapeutic-dose group at 1.9% versus 0.9% prophylaxis group, though this did not reach statistical significance. Many of the secondary outcomes in this trial were promising. The rate of major thrombotic event (8.0% vs 9.9%, OR 0.72, 95% CI 0.53 to 0.90) were lower and the rate of survival without organ support at 28 days (79.3% vs 75.4%, OR 1.3, 95% CI 1.05 to 1.61) was higher in the treatment-dose group. Patients on full dose heparin had an 80.2% of survival to hospital discharge, compared to 76.4% in usual care group, which did not reach statistical significance. As occurred in the severe group, there were moderate patients in the standard of care arm treated with an intermediate dose of heparin or LMWH, however, it was only about a quarter of patients. In addition, 20% of patients in the experimental group received lower than full therapeutic dose of heparin in the first two days after randomization. 53 RAPID was a randomized control trial evaluating treatment of hospitalized non-ICU patients with either treatment dose or prophylactic dose anticoagulation. 55 This study enrolled 465 patients and at interim analysis was found to be underpowered to reach their primary endpoint which was a composite of ICU admission, non-invasive or invasive ventilation, or mortality at 28 days. There was, however, a significant decrease in the individual secondary outcomes of all-cause mortality (1.8% vs 7.6%) and an increase in mean ventilator-free days. There was no significant difference in need for ICU admission, venous or arterial thromboembolism, or ISTH defined major bleeding. Additionally, unlike the results of the pooled multiplatform trials, only 1.7% of the prophylactic dose patients received an "intermediate" dose for SOC and 2.6% of the treatment dose arm patients received a reduced "therapeutic" dose. 55 In addition to therapeutic versus prophylactic dose anticoagulation, a trial designed specifically to test the intermediate dose strategy was proposed to minimize bleeding risk in severely ill patients. The INSPIRATION trial enrolled 562 patients in an ICU setting randomized to prophylactic dose enoxaparin 40mg daily (with adjustments for renal function) versus an intermediate dose regimen of 1mg/kg daily. In this study, there was no significant difference in the rate of venous or arterial thrombosis, organ support on ECMO, or mortality at 30 days. 56 Utilization of D-dimer in COVID-19

Many clinical labs have been proposed to prognosticate risk of thrombosis in COVID-19, with Ddimer receiving considerable attention. D-dimer is a degradation product of fibrin formation and prior to COVID-19 was used to rule out PE in patients with a low pre-test probability. 57 In COVID-19, many studies have demonstrated that elevated D-dimer levels are associated with an increased risk of disease progression and/or mortality. 44, [58] [59] [60] In one study, only 24% of survivors of COVID-19 were found to have a d-dimer >1 µg/mL whereas 81% of non-survivors had d-dimer >1 µg/mL. 35 A similar study found that 85% of patients with a d-Dimer >3 µg/mL did not survive, suggesting prognostic value to the test. 2 D-dimer is very commonly elevated during acute SARS-CoV-2 infection, particularly in hospitalized patients, rendering d-dimer of limited use in the assessment of VTE. 54, 61 In a study of people with suspected PEs with COVID-19, 91% of patients without PEs had an elevated d-dimer (0.05ug/ml or >). The same d-dimer cutoff yielded a 100% negative predictive value but only a 14% positive predictive value. 62 Another study evaluating COVID-19 patients with d-dimer levels > 1,000 ng/mL found that only 14.7% had asymptomatic DVT. 63 Though higher cut-off values were more likely to be associated with DVT, there is currently no consensus on the d-dimer cut-off that should prompt further imaging. D-dimer elevations may be due to microthrombotic events and DIC, which are not assessed by imaging modalities. Specifically, at high risk are microthrombosis within the pulmonary vasculature due to regional inflammatory response. Due to this concern, researchers began looking at whether anticoagulation would affect outcomes in COVID-19 patients with elevated d-dimers. Notably, treatment effects stratified by d-dimer yielded inconsistent results. One study of ~450 patients which found no overall difference in 28-day mortality with anticoagulation in hospitalized COVID-19 patients, demonstrated a significant reduction in mortality in patients with sepsis induced coagulopathy (SIC) score >4 or a d-dimer > 6x upper limit of normal. 64 A subsequent study in which there was a prespecified analysis of patients stratified by d-dimer, reported no significant differences in treatment effect in critically ill patients with high versus low d-dimers. 54 In non-critically ill COVID-19 patients, the probability of superiority for therapeutic anticoagulation was slightly more in the high d-dimer group (97.3%) compared to the low d-dimer group (92.9%), but regardless of the d-dimer value, therapeutic anticoagulation was superior to prophylactic dosing. 53 There are several caveats when assessing the use of d-dimer in COVID-19. D-dimer can be measured using numerous assays, protocols vary across clinical labs and the results are reported in many different units, collectively, making comparison across institutions challenging. 65 (Johnson, Am J of Hematology, 2019) Prior to COVID-19, studies utilizing age-adjusted values for d-dimer were better able to exclude PE in patients. 66 Age adjustment of d-dimer was done in few studies described herein, despite older patients being well represented in clinical trials of COVID-19. 62 D-dimer elevations can persist in 25% of people for at least four months after acute SARS-CoV-2 infection. 62, 67 Additionally, many factors can elevate a d-dimer including age, liver disease, malignancy, pregnancy and sepsis, rendering interpretation in COVID-19 patients with other conditions less straightforward. 65 In summary, an elevated d-dimer is common in COVID-19, particularly in critically ill patients. If a patient with COVID-19 has a low d-dimer, VTE is unlikely. Multiple studies demonstrate that the higher the d-dimer the greater the likelihood of VTE and poor clinical outcomes, but there is no consensus across studies regarding the cutoff value for d-dimer to prompt imaging in COVID-19. Further study is needed before an isolated elevation in a D-dimer is sufficient to justify empiric full dose anticoagulation or trigger evaluations for PE or DVTs in the setting of SARS-CoV-2 infection.

The American Society of Hematology (ASH) suggests the use of prophylactic over intermediate dose (recommendation 1A) and prophylactic over therapeutic dose anticoagulation (recommendation 1B) in critically ill patients with COVID-19. These suggestions apply to patients who should be admitted to an ICU due to "an immediate life-threatening condition" and do not have suspected or confirmed VTE. ASH suggests the use of therapeutic dose over prophylactic dose anticoagulation (recommendation 1B) in patients with acute illness due to COVID-19. This recommendation applies to patients who are not critically ill, do not have suspected or confirmed VTE or another condition requiring treatment dose anticoagulation. 68 J o u r n a l P r e -p r o o f

The NIH recommends therapeutic heparin dosing for hospitalized patients on low flow oxygen with elevated D-dimers who are not in the ICU and without known contraindications (CIIa). They recommend prophylactic heparin dosing in ICU patients with COVID-19 (AI). For patients transferred from the floor to the ICU the NIH recommends switching from therapeutic to prophylactic dose heparin (BIII). The NIH does not recommend prophylactic anticoagulation or antiplatelet therapy in outpatients with COVID-19(AIIa). The aforementioned recommendations apply to COVID-19 patients without confirmed or suspected VTE. The NIH reports insufficient evidence to recommend routine screening for VTE in all COVID-19 patients, irrespective of their coagulation values, however, in hospitalized patients with sudden clinical deteriorations they recommend assessment for VTE (AIII). The NIH recommends patients on chronic anticoagulation or antiplatelet treatments at home continue those during their acute COVID-19 illness (AIII). 25 

Given the aforementioned reduction in organ support-free days shown in ACTIV-4A, we recommend use of full dose IV heparin to treat moderately ill patients (those on < 20L O2) admitted to the hospital with COVID-19. This may reflect effects of heparin beyond ATIII inhibition include degradation of NETs and mitigation of the SARS-CoV-2 spike protein binding, but further mechanistic studies are needed. 15, 69, 70 Conclusion COVID-19 patients are prone to venous, cerebrovascular and coronary thrombi, particularly those with severe disease. The pathogenesis is multifactorial involving proinflammatory cascades and development of coagulopathy, but further investigations are needed to elucidate the mechanisms by which host-viral interactions promote thrombus formation. Elevated D-dimers are common in patients with COVID-19 and cannot be used in isolation to predict VTE in people with SARS-CoV-2. If given early in hospital admission, therapeutic dose heparin improves clinical outcomes in patients with moderate COVID-19. To date anti-thrombotics have not improved outcomes in patients with severe COVID-19, possibly because significant tissue damage has already occurred. Finally, prompt recognition of extrapulmonary thrombi-particularly in the brain and heart-may be beneficial, but additional studies are needed and interventional response times may be limited by local resources.

Coagulopathy in COVID-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: A meta-analysis of 35 studies and 6427 patients

Blood coagulation in immunothrombosis-at the frontline of intravascular immunity

Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis

COVID-19 update: Covid-19-associated coagulopathy

Neutrophil extracellular traps kill bacteria

Neutrophil extracellular traps (NETs) in severe SARS-CoV-2 lung disease

Extracellular DNA traps promote thrombosis

Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury

Neutrophil accumulation and NET release contribute to thrombosis in HIT

The emerging role of NETs in venous thrombosis and immunothrombosis

SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Vascular occlusion by neutrophil extracellular traps in COVID-19

Neutrophil extracellular traps in COVID-19

Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19

Neutrophil extracellular traps activate IL-8 and IL-1 expression in human bronchial epithelia

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

COVID-19, immunothrombosis and venous thromboembolism: Biological mechanisms

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19)

Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19

19 treatment guidelines in COVID-19: Antithrombotic therapy

Ischemic stroke occurs less frequently in patients with COVID-19: A multicenter cross-sectional study

Acute ischemic stroke and COVID-19: An analysis of 27 676 patients

Stroke in COVID-19: A systematic review and metaanalysis

Increased risk of acute stroke among patients with severe COVID-19: A multicenter study and meta-analysis

The relationship between COVID-19's severity and ischemic stroke: A systematic review and meta-analysis

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in china

ST-segment elevation in patients with covid-19 -A case series

Clinical features of patients infected with 2019 novel coronavirus in wuhan, china

Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, china: A retrospective cohort study

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in wuhan, china

Experiences and lesson strategies for cardiology from the COVID-19 outbreak in wuhan, china, by 'on the scene' cardiologists

High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction

Multiple spontaneous coronary thrombosis causing ST-elevation myocardial infarction in a patient with COVID-19

Microthrombi as a major cause of cardiac injury in COVID-19: A pathologic study

ST-elevation myocardial infarction in patients with COVID-19: Clinical and angiographic outcomes

Endothelial cells: Role in infection and inflammation

Acute myocardial infarction after laboratory-confirmed influenza infection

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, china

Management of acute myocardial infarction during the COVID-19 pandemic: A position statement from the society for cardiovascular angiography and interventions (SCAI), the american college of cardiology (ACC), and the american college of emergency physicians (ACEP)

Clinical characteristics of coronavirus disease 2019 in china

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): A structured summary of a study protocol for a randomized controlled trial

Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: The ACTIV-4B randomized clinical trial

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial

Anticoagulation in COVID-19: Effect of enoxaparin, heparin, and apixaban on mortality

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial

Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

Therapeutic anticoagulation with heparin in critically ill patients with covid-19

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

Effect of intermediate-dose vs standarddose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial

Validity and clinical utility of the simplified wells rule for assessing clinical probability for the exclusion of pulmonary embolism

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in new york city: A prospective cohort study

Estimation of admission D-dimer cutoff value to predict venous thrombotic events in hospitalized COVID-19 patients: Analysis of the SEMI-COVID-19 registry

D-dimer, disease severity, and deaths (3D-study) in patients with COVID-19: A systematic review and meta-analysis of 100 studies

Prevalence and outcomes of D-dimer elevation in hospitalized patients with COVID-19. Arteriosclerosis, thrombosis, and vascular biology

D-dimer testing for the exclusion of pulmonary embolism among hospitalized patients with COVID-19

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

The d-dimer assay

Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: The ADJUST-PE study

Prolonged elevation of d-dimer levels in convalescent COVID-19 patients is independent of the acute phase response

American society of hematology guidelines on anticoagulation in patients with COVID-19

SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2

The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms